talquetamab,elranatamab
pfizer,janssen
['elranatamab', 'talquetamab']
myeloma oral abstracts: 1. talquetamab sc qw (bispecific antibody targeting both gprc5d and cd3 receptors). orr 73%. sepsis 57% (g3/4 19%) 2. elranatamab (2 abstracts) (bispecific antibody targeting both bcma and cd3 receptors). orr 61%, sepsis 61% (g3/4 35%) #ash22
Guidelines, updates, Questions, Meetings in Hematology.